Tags

Gamma-hydroxybutyric acid (GHB) is a substance that is classified under two different categories by the United States Drug Enforcement Administration (DEA). GHB is produced in a legal form (trade name: Xyrem [sodium oxybate]) that is approved for the treatment of narcolepsy. Xyrem falls under the Schedule III controlled substance classification by the DEA. As a […]

GHB, or gamma-hydroxybutyrate, is a short-chained fatty acid metabolite of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is a naturally occurring substance found in various mammalian tissues but is also produced as a pharmaceutical known as sodium oxybate (trade name Xyrem)—an FDA approved medication used to treat narcolepsy, a sleep disorder. In this form, the […]

GHB is a naturally occurring substance in the human central nervous system that occurs as a result of the metabolism of the inhibitory neurotransmitter gamma–aminobutyric acid. GHB can also be manufactured artificially, and the term GHB typically refers to the illicit chemical substance that is essentially the same as the medicinal drug Xyrem (sodium oxybate), […]

Gamma-Hydroxybutyric acid (GHB) is a metabolite of the neurotransmitter GABA (gamma-aminobutyric acid), the major inhibitory neurotransmitter in the central nervous system. A metabolite is a substance that is formed during the normal process of metabolism. As GABA is broken down, one of the byproducts is GHB. GHB is classified as a central nervous system depressant, […]